Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

NCT06077773 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

113

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic Business Decision

Conditions

Chronic Spontaneous Urticaria

Interventions

DRUG: Oral EP262
DRUG: Placebo

Sponsor

Escient Pharmaceuticals, Inc